Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294891 · ClinicalTrials.gov registry record
Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease
A clinical trial of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 6
- Enrollment target
- 1
- Study location
NCT01294891 is a study of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria that has completed, run by Oregon Health and Science University. The registered enrollment target is 6 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01294891, a study of Sickle Cell Disease and Paroxysmal Nocturnal Hemoglobinuria, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of the heart and kidney. To test this question, the investigators will perform imaging tests (contrast ultrasound perfusion imaging) to look at the flow and function of these microvessels and compare this information to heart and kidney function. To further look at this question, patients who have PNH will be studied before and after starting a new drug (Soliris) that decreases damage to blood cells. In patients with sickle cell disease, patients will be studied at baseline (not during a pain crisis) and also during a pain crisis if one develops.
Conditions Studied
Interventions
- OTHER Imaging
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01294891
The ClinicalTrials.gov registry entry for NCT01294891 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Imaging is the first listed.
NCT01294891 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT01294891 about?
NCT01294891 is a clinical study titled "Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease". The purpose of this study is to examine how abnormal blood flow in the small vessels (microvessels) of the heart, muscle and kidney in paroxysmal nocturnal hemoglobinuria (PNH) or sickle cell disease leads to poor functioning of the heart and kidney. To test this question, the investigators will per...
What is the current status of trial NCT01294891?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2011-02. Estimated completion is 2014-10.
What conditions does trial NCT01294891 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Paroxysmal Nocturnal Hemoglobinuria, Rheologic Disease.
What interventions are being tested in trial NCT01294891?
The interventions under investigation include: Imaging (OTHER).
Who is sponsoring clinical trial NCT01294891?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01294891 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.